Concerns about the safety of obesity agents from a manufacturing perspective

Postgraduate Medicine

Volumn 120, Issue 2, 2008, Pages 42-45

  Kanfer, Isadore ^a  

^a RHODES UNIVERSITY   (South Africa)

Author keywords

Bioequivalence; Hydrochloride salt; Mesylate salt; Pharmaceutical equivalence; Sibutramine

Indexed keywords

BENZATROPINE MESILATE; BETAHISTINE MESYLATE; BITOLTEROL MESILATE; BROMOCRIPTINE MESILATE; CHLORIDE; DEFEROXAMINE MESYLATE; DELAVIRDINE; DIHYDROERGOCRISTINE; DIHYDROERGOTAMINE; DOXAZOSIN MESYLATE; GEMIFLOXACIN; GENERIC DRUG; HISTAMINE DERIVATIVE; IMATINIB; MESYLIC ACID DERIVATIVE; NELFINAVIR; OBATOCLAX; PAROXETINE; PERGOLIDE MESILATE; REBOXETINE; SAQUINAVIR; SIBUTRAMINE; UNCLASSIFIED DRUG; ANTIOBESITY AGENT; CYCLOBUTANE DERIVATIVE;

ARTICLE; ASTHMA; BACTERIAL INFECTION; CHRONIC MYELOID LEUKEMIA; DEPRESSION; DRUG CONTROL; DRUG EFFICACY; DRUG IMPURITY; DRUG MANUFACTURE; DRUG QUALITY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; HEALTH HAZARD; HYPERTENSION; MENIERE DISEASE; MIGRAINE; NEOPLASM; OBESITY; PARKINSON DISEASE; UNITED STATES; VIRUS INFECTION; CHEMISTRY; HUMAN; PHARMACOKINETICS; REVIEW;

ANTI-OBESITY AGENTS; CHEMISTRY, PHARMACEUTICAL; CYCLOBUTANES; DRUGS, GENERIC; HUMANS; MESYLATES; THERAPEUTIC EQUIVALENCY;

EID: 54049138100     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2008.07.1789     Document Type: Article

References (13)

1. Pfizer warns health care professionals of possible carcinogen in Viracept. AIDS Reader. 2007;17(11):528.
2. Viracept contaminated in Europe. AIDS Patient Care STDs. 2007;21(7):521.
3. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med. 2004;164(9):994-1003. (Pubitemid 38581520)
4. Kim EJ, Park EK, Suh KH. Safety pharmacology of sibutramine mesylate, an anti-obesity drug. Human Exper Toxicol. 2005;24(3):109-119. (Pubitemid 40605151)
5. 21 Code of Federal Regulations. Part 210 - Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs. General Part 211 - Current good manufacturing practice for finished pharmaceuticals. http://www.fda.gov/cder/dmpq/cgmpregs.htm. Created August 29, 1996. Last updated December 6, 2007. Accessed May 2, 2008.
6. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use - Impurities in New Drug Substances Q3A (R2). October 25, 2006.
7. European Medicines Evaluation Agency. European Medicines Evaluation Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on the limits of genotoxic impurities. CPMP/SWP/5199/02. London, England. June 28, 2006.
8. Schweitzer SO. Trying times at the FDA - Challenge of ensuring the safety of imported pharmaceuticals. N Engl J Med. 2008;358(17):1773-1777.
9. Verbeeck RK, Kanfer I, Walker RB. Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy. Eur J Pharm Sci. 2006;28(1-2):1-6.
10. Walker RB, Verbeek RK, Kanfer I. Pharmaceutical alternatives: considerations for generic substitution. In: Kanfer I, Shargel L, eds. Generic Drug Product Development: Bioequivalence Issues. New York, NY: Informa Healthcare; 2008:31-45.
11. Snodin DJ. Residues of genotoxic alkyl mesylates in mesylate salt drug substances: real or imaginary problems. Reg Toxicol Pharmacol. 2006;45(1):79-90.
12. Francis PA. Viracept contamination. http://www.pharmabiz.com/article/ detnews.asp?SecArch=&articleid=40940§ionid=47. Published October 4, 2007. Accessed April 30, 2008.
13. Lewcock A. Regulators slate Roche 'lack of knowledge and understanding' in Viracept contamination case. http://www.gmptrainingsystems.com/PDF/Roche- contamination.pdf. Published November 23, 2007. Accessed April 30, 2008.